Combination thymosin α and lymphoblastoid interferon treatment in chronic hepatitis C
Gut, ISSN: 0017-5749, Vol: 39, Issue: 5, Page: 679-683
1996
- 52Citations
- 11Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations52
- Citation Indexes52
- 52
- CrossRef37
- Captures11
- Readers11
- 11
Article Description
Background - Monotherapy for chronic hepatitis C using interferon (IFN) results in a very small proportion of patients exhibiting a sustained response. Clinical trials assessing the benefit of combination drug therapy may provide evidence of improved treatment response over that seen with single drug treatment. Aim - To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin α (Tα), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly. Patients and Methods - Fifteen patients with serum HCV RNA positive chronic hepatitis C were studied. Eleven patients were treatment naive and four had failed previous standard IFN therapy. Thirteen patients were HCV RNA serotype 1b. All patients were given combination Tα and L-IFN therapy for one year with a six month follow up period. Results - Six months after initiation of treatment seven patients (47%) were sera HCV RNA negative and at completion of the one year treatment 11 (73%), including two who had failed previous standard IFN treatment, had negative serum HCV RNA. Six months after treatment, six patients (40%), including five with HCV type 1b, showed a sustained response characterised by a negative serum HCV RNA. Conclusions - The results of this open label trial suggest that there may be a potential benefit to combining an immune modulator (Tα) with an antiviral (IFN) in the treatment of chronic hepatitis C. Verification of the observations in this study require completion of a randomised controlled study.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030452149&origin=inward; http://dx.doi.org/10.1136/gut.39.5.679; http://www.ncbi.nlm.nih.gov/pubmed/9026482; https://gut.bmj.com/lookup/doi/10.1136/gut.39.5.679; https://dx.doi.org/10.1136/gut.39.5.679; https://gut.bmj.com/content/39/5/679
BMJ
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know